CN109715788A - 用于免疫疗法的t细胞组合物 - Google Patents

用于免疫疗法的t细胞组合物 Download PDF

Info

Publication number
CN109715788A
CN109715788A CN201780053540.8A CN201780053540A CN109715788A CN 109715788 A CN109715788 A CN 109715788A CN 201780053540 A CN201780053540 A CN 201780053540A CN 109715788 A CN109715788 A CN 109715788A
Authority
CN
China
Prior art keywords
cell
antigen
virus
composition
target antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780053540.8A
Other languages
English (en)
Chinese (zh)
Inventor
A.E.斯莱恩茨
T.Y.纳卡加瓦
M.A.赫尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kingius Biotechnology Co
Original Assignee
Kingius Biotechnology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kingius Biotechnology Co filed Critical Kingius Biotechnology Co
Publication of CN109715788A publication Critical patent/CN109715788A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780053540.8A 2016-06-28 2017-06-28 用于免疫疗法的t细胞组合物 Pending CN109715788A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662355506P 2016-06-28 2016-06-28
US201662355533P 2016-06-28 2016-06-28
US201662355458P 2016-06-28 2016-06-28
US62/355506 2016-06-28
US62/355533 2016-06-28
US62/355458 2016-06-28
PCT/US2017/039846 WO2018005712A1 (en) 2016-06-28 2017-06-28 T cell compositions for immunotherapy

Publications (1)

Publication Number Publication Date
CN109715788A true CN109715788A (zh) 2019-05-03

Family

ID=60787739

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053540.8A Pending CN109715788A (zh) 2016-06-28 2017-06-28 用于免疫疗法的t细胞组合物

Country Status (11)

Country Link
US (2) US20200237819A1 (https=)
EP (1) EP3487990A4 (https=)
JP (3) JP7034955B2 (https=)
KR (1) KR20190037243A (https=)
CN (1) CN109715788A (https=)
AU (3) AU2017290119A1 (https=)
CA (1) CA3068387A1 (https=)
IL (1) IL263896A (https=)
MX (1) MX2019000180A (https=)
SG (1) SG11201811745UA (https=)
WO (1) WO2018005712A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113481157A (zh) * 2021-07-21 2021-10-08 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞的优化制备方法
CN113512529A (zh) * 2021-07-21 2021-10-19 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ab的制备方法
CN113564116A (zh) * 2021-07-21 2021-10-29 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
US20180072990A1 (en) * 2015-03-20 2018-03-15 Children's National Medical Center Generating virus or other antigen-specific t cells from a naïve t cell population
HUE066460T2 (hu) 2016-10-26 2024-08-28 Iovance Biotherapeutics Inc A kriokonzervált tumor infiltráló limfociták restimulációja
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
CN110199017A (zh) 2017-01-20 2019-09-03 国立大学法人京都大学 CD8α+β+细胞毒性T细胞的制备方法
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW201930340A (zh) * 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP7198602B2 (ja) * 2018-07-11 2023-01-04 カワサキモータース株式会社 自動二輪車
EP3831936A4 (en) * 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS
AU2019314888A1 (en) * 2018-07-31 2021-02-18 Polybiocept Gmbh Production and selection of tumor uber reactive immune cells (TURICs)
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法
EP3834833A4 (en) * 2018-08-10 2022-05-18 Eutilex Co., Ltd. CANCER ANTIGEN-SPECIFIC CYTOTOXIC T-CELLS
JP7632868B2 (ja) * 2018-10-26 2025-02-19 国立大学法人信州大学 高効率な遺伝子改変細胞の作製方法
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
US20220064597A1 (en) * 2018-12-18 2022-03-03 Beth Israel Deaconess Medical Center, Inc. Generation of organoid-primed T (opT) cells with memory phenotype
WO2020146434A2 (en) * 2019-01-07 2020-07-16 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
JP7649244B2 (ja) * 2019-02-14 2025-03-19 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 免疫細胞の効力をアッセイするための刺激剤の使用
JP7668226B2 (ja) * 2019-03-30 2025-04-24 ビオンテック ユーエス インコーポレイテッド Ｔ細胞組成物を調製するための組成物および方法、ならびにそれらの使用
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
EP3976068A4 (en) * 2019-05-31 2023-08-09 Children's National Medical Center CYTOKINE COCKTAILS FOR SELECTIVE T-LYMPHOCYTE SUBSET EXPANSION
WO2020263919A1 (en) * 2019-06-24 2020-12-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
US20230032934A1 (en) * 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
EP4081226A4 (en) * 2019-12-23 2024-03-27 Baylor College of Medicine T CELL PERFORMANCE ASSAY AS A PROGNOSIS FACTOR FOR CLINICAL OUTCOME
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022115641A2 (en) * 2020-11-25 2022-06-02 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
US20250130220A1 (en) * 2021-09-08 2025-04-24 KSQ Therapeutics, Inc. Lymphocyte potency assay
EP4412628A1 (en) * 2021-10-08 2024-08-14 Baylor College of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
JP2023064787A (ja) * 2021-10-27 2023-05-12 国立大学法人京都大学 Ｔ細胞の品質評価方法、および当該方法に用いる試薬
US20250223552A1 (en) * 2022-03-18 2025-07-10 St. Jude Children's Research Hospital, Inc. Method for preparing t cells for adoptive t cell therapy
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
KR102566680B1 (ko) * 2022-09-28 2023-08-14 (주)포에버엔케이 면역세포 및 자연살해세포 배양을 위한 신규한 이중배양 제조방법 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023377A1 (en) * 1998-05-11 2004-02-05 Mario Assenmacher Direct selection of antigen-specific T cells, compositions obtained thereby and methods of use thereof
US20130058909A1 (en) * 2010-05-17 2013-03-07 Duke University Methods of treatment using ex vivo expansion of cord blood t cells
US20140099341A1 (en) * 2011-05-26 2014-04-10 Alfred E. Slanetz Modulated Immunodominance Therapy
US20160068811A1 (en) * 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble Antibody Complexes For T Cell or NK Cell Activation and Expansion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015070A2 (en) 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
EP3234130B1 (en) * 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
HK1255161A1 (zh) * 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023377A1 (en) * 1998-05-11 2004-02-05 Mario Assenmacher Direct selection of antigen-specific T cells, compositions obtained thereby and methods of use thereof
US20130058909A1 (en) * 2010-05-17 2013-03-07 Duke University Methods of treatment using ex vivo expansion of cord blood t cells
US20140099341A1 (en) * 2011-05-26 2014-04-10 Alfred E. Slanetz Modulated Immunodominance Therapy
US20160068811A1 (en) * 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble Antibody Complexes For T Cell or NK Cell Activation and Expansion

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
CN113481157A (zh) * 2021-07-21 2021-10-08 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞的优化制备方法
CN113512529A (zh) * 2021-07-21 2021-10-19 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ab的制备方法
CN113564116A (zh) * 2021-07-21 2021-10-29 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法
CN113512529B (zh) * 2021-07-21 2022-11-25 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ab的制备方法
CN113564116B (zh) * 2021-07-21 2023-08-01 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法

Also Published As

Publication number Publication date
KR20190037243A (ko) 2019-04-05
IL263896A (en) 2019-01-31
JP2022066355A (ja) 2022-04-28
AU2023254998A1 (en) 2023-11-16
SG11201811745UA (en) 2019-01-30
JP2019519246A (ja) 2019-07-11
CA3068387A1 (en) 2018-01-04
US20230145991A1 (en) 2023-05-11
JP7034955B2 (ja) 2022-03-14
EP3487990A1 (en) 2019-05-29
EP3487990A4 (en) 2020-07-29
WO2018005712A1 (en) 2018-01-04
US20200237819A1 (en) 2020-07-30
AU2026202260A1 (en) 2026-04-09
MX2019000180A (es) 2019-11-05
JP2024103547A (ja) 2024-08-01
AU2017290119A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
US20230145991A1 (en) T cell compositions for immunotherapy
Parkhurst et al. Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression
AU2011212794B2 (en) ICOS critically regulates the expansion and function of inflammatory human Th17 cells
Swain et al. Homeostasis and the age-associated defect of CD4 T cells
CN110662834B (zh) 使用转化的t细胞培养自然杀伤细胞的方法
EP2899269B1 (en) Method for cloning t cell receptor
KR20170121178A (ko) 보편적인 살해 t-세포
KR20170067751A (ko) 저산소 및 정상산소 교대 조건에서 골수 침윤성 림프구의 활성화
AU2023221021B2 (en) Compositions and methods for antigen-specific t cell expansion
US20260078340A1 (en) Scaffolds with stabilized mhc molecules for immune-cell manipulation
JP2022512538A (ja) Ｅｂｖ関連がんの処置のための抗ｌｍｐ２ ｔｃｒ－ｔ細胞療法
JP2018511320A (ja) 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節法
Adair et al. Avidity of human T cell receptor engineered CD4+ T cells drives T-helper differentiation fate
US20240252644A1 (en) Person-tailored t cell composition targeting merkel cell carcinoma
Reimann et al. Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains
CN102596209A (zh) 含有短暂性存活ctl的医药品组合物
JP6508873B2 (ja) 抗原特異的ｔ細胞受容体の取得方法
Titov et al. Adoptive Immunotherapy beyond CAR T-Cells. Cancers 2021, 13, 743
Purcarea T cell receptor-dependent protection, recruitment and phenotypes of OVA-specific CD8+ T cells with different avidities in a murine MC38-OVA tumor model
Sakellariou-Thompson Bringing Til Therapy Beyond Melanoma: Advancing The Treatment of Advanced Pancreatic and Ovarian Cancers
RU2023104429A (ru) Композиции и способы для производства t-клеток
Bleakley et al. Activation induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8 Tcells responding to antigen without requiring knowledge of epitope specificities
HK40003131A (zh) Cacna1h衍生的肿瘤抗原多肽及其应用
HK40010495A (en) Col14a1-derived tumour antigen polypeptide and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination